Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2019

Open Access 01-12-2019 | Insulins | Original investigation

Plasma omentin levels are inversely associated with atherosclerosis in type 2 diabetes patients with increased plasma adiponectin levels: a cross-sectional study

Authors: Masami Nishimura, Tomoaki Morioka, Mariko Hayashi, Yoshinori Kakutani, Yuko Yamazaki, Masafumi Kurajoh, Katsuhito Mori, Shinya Fukumoto, Atsushi Shioi, Tetsuo Shoji, Masaaki Inaba, Masanori Emoto

Published in: Cardiovascular Diabetology | Issue 1/2019

Login to get access

Abstract

Background

Omentin and adiponectin are among the anti-inflammatory and anti-atherogenic adipokines that have potentially beneficial effects on cardiovascular disorders. Recent studies indicate a paradoxical relationship between adiponectin and cardiovascular mortality across many clinical settings including type 2 diabetes. In this study, we characterized the clinical features of type 2 diabetes patients with increased adiponectin levels and examined the association between omentin and atherosclerosis in those patients.

Methods

The subjects were 413 patients with type 2 diabetes. Fasting plasma omentin and total adiponectin levels were measured by enzyme-linked immunosorbent assay. The intima-media thickness (IMT) of the common carotid artery was measured by ultrasonography. The subjects were stratified according to the median value of plasma adiponectin.

Results

In high-adiponectin group, omentin levels were higher, while IMT tended to be greater than those in low-adiponectin group. The high-adiponectin group also exhibited older age, higher systolic blood pressure, lower kidney function, body mass index, and insulin resistance index compared to the low-adiponectin group. Multivariate analysis revealed that omentin levels were independently and negatively associated with IMT in high-adiponectin group, but not in low-adiponectin group, after adjusting for adiponectin levels and traditional cardiovascular risk factors. On the other hand, adiponectin levels were not significantly associated with IMT in either group.

Conclusions

Plasma omentin levels are inversely associated with IMT in type 2 diabetes patients with increased adiponectin levels and multiple cardiovascular risk factors. This study suggests a protective role of omentin against atherosclerosis in type 2 diabetes patients, which is potentially influenced by adiponectin level and cardiovascular risk status.
Appendix
Available only for authorised users
Literature
1.
Tsuji S, Uehori J, Matsumoto M, Suzuki Y, Matsuhisa A, Toyoshima K, Seya T. Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem. 2001;276:23456–63.PubMedCrossRef
2.
Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006;290:E1253–61.PubMedCrossRef
3.
Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 2010;88:29–33.PubMedCrossRef
4.
de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56:1655–61.PubMedCrossRef
5.
Yan P, Liu D, Long M, Ren Y, Pang J, Li R. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2011;119:257–63.PubMedCrossRef
6.
Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol. 2011;10:103.PubMedPubMedCentralCrossRef
7.
Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med. 2010;20:143–8.PubMedCrossRef
8.
9.
Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, Ohashi K, Ikeda N, Kihara S, Murohara T. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis. 2011;219:811–4.PubMedCrossRef
10.
Biscetti F, Nardella E, Bonadia N, Angelini F, Pitocco D, Santoliquido A, Filipponi M, Landolfi R, Flex A. Association between plasma omentin-1 levels in type 2 diabetic patients and peripheral artery disease. Cardiovasc Diabetol. 2019;18:74.PubMedPubMedCentralCrossRef
11.
Kadoglou NP, Lambadiari V, Gastounioti A, Gkekas C, Giannakopoulos TG, Koulia K, Maratou E, Alepaki M, Kakisis J, Karakitsos P, et al. The relationship of novel adipokines, RBP4 and omentin-1, with carotid atherosclerosis severity and vulnerability. Atherosclerosis. 2014;235:606–12.PubMedCrossRef
12.
Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernandez-Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring). 2011;19:1552–9.CrossRef
13.
Liu R, Wang X, Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract. 2011;93:21–5.PubMedCrossRef
14.
Shibata R, Takahashi R, Kataoka Y, Ohashi K, Ikeda N, Kihara S, Murohara T, Ouchi N. Association of a fat-derived plasma protein omentin with carotid artery intima-media thickness in apparently healthy men. Hypertens Res. 2011;34:1309–12.PubMedCrossRef
15.
Xu T, Zuo P, Cao L, Gao Z, Ke K. Omentin-1 is associated with carotid plaque instability among ischemic stroke patients. J Atheroscler Thromb. 2018;25:505–11.PubMedPubMedCentralCrossRef
16.
Hayashi M, Morioka T, Hatamori M, Kakutani Y, Yamazaki Y, Kurajoh M, Motoyama K, Mori K, Fukumoto S, Shioi A, et al. Plasma omentin levels are associated with vascular endothelial function in patients with type 2 diabetes at elevated cardiovascular risk. Diabetes Res Clin Pract. 2019;148:160–8.PubMedCrossRef
17.
18.
Kubota M, Yoneda M, Maeda N, Ohno H, Oki K, Funahashi T, Shimomura I, Hattori N. Westernization of lifestyle affects quantitative and qualitative changes in adiponectin. Cardiovasc Diabetol. 2017;16:83.PubMedPubMedCentralCrossRef
19.
Kizer JR. Adiponectin, cardiovascular disease, and mortality: parsing the dual prognostic implications of a complex adipokine. Metabolism. 2014;63:1079–83.PubMedPubMedCentralCrossRef
20.
Menzaghi C, Trischitta V. The adiponectin paradox for all-cause and cardiovascular mortality. Diabetes. 2018;67:12–22.PubMedCrossRef
21.
Gasbarrino K, Gorgui J, Nauche B, Cote R, Daskalopoulou SS. Circulating adiponectin and carotid intima-media thickness: A systematic review and meta-analysis. Metabolism. 2016;65:968–86.PubMedCrossRef
22.
American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(Suppl 1):S14–80.CrossRef
23.
Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1:212–28.CrossRef
24.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.PubMedCrossRef
25.
Asada M, Morioka T, Yamazaki Y, Kakutani Y, Kawarabayashi R, Motoyama K, Mori K, Fukumoto S, Shioi A, Shoji T, et al. Plasma C1q/TNF-related protein-9 levels are associated with atherosclerosis in patients with type 2 diabetes without renal dysfunction. J Diabetes Res. 2016;2016:8624313.PubMedPubMedCentralCrossRef
26.
Yanase T, Nasu S, Mukuta Y, Shimizu Y, Nishihara T, Okabe T, Nomura M, Inoguchi T, Nawata H. Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope. Am J Hypertens. 2006;19:1206–12.PubMedCrossRef
27.
Ramos LF, Shintani A, Ikizler TA, Himmelfarb J. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol. 2008;19:593–9.PubMedPubMedCentralCrossRef
28.
Kizer JR, Arnold AM, Strotmeyer ES, Ives DG, Cushman M, Ding J, Kritchevsky SB, Chaves PH, Hirsch CH, Newman AB. Change in circulating adiponectin in advanced old age: determinants and impact on physical function and mortality The Cardiovascular Health Study All Stars Study. J Gerontol A Biol Sci Med Sci. 2010;65:1208–14.PubMedCrossRef
29.
Heidari M, Nasri P, Nasri H. Adiponectin and chronic kidney disease; a review on recent findings. J Nephropharmacol. 2015;4:63–8.PubMedPubMedCentral
30.
Baden MY, Yamada Y, Takahi Y, Obata Y, Saisho K, Tamba S, Yamamoto K, Umeda M, Furubayashi A, Tsukamoto Y, et al. Association of adiponectin with blood pressure in healthy people. Clin Endocrinol (Oxf). 2013;78:226–31.CrossRef
31.
Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tanaka S, Ouchi N, Kihara S, Funahashi T, et al. Adiponectin in essential hypertension. J Nephrol. 2002;15:507–11.PubMed
32.
Sardu C, Pieretti G, D’Onofrio N, Ciccarelli F, Paolisso P, Passavanti MB, Marfella R, Cioffi M, Mone P, Dalise AM, et al. Inflammatory cytokines and SIRT1 levels in subcutaneous abdominal fat: relationship with cardiac performance in overweight pre-diabetics patients. Front Physiol. 2018;9:1030.PubMedPubMedCentralCrossRef
33.
Hiramatsu-Ito M, Shibata R, Ohashi K, Uemura Y, Kanemura N, Kambara T, Enomoto T, Yuasa D, Matsuo K, Ito M, et al. Omentin attenuates atherosclerotic lesion formation in apolipoprotein E-deficient mice. Cardiovasc Res. 2016;110:107–17.PubMedCrossRef
34.
Uemura Y, Shibata R, Kanemura N, Ohashi K, Kambara T, Hiramatsu-Ito M, Enomoto T, Yuasa D, Joki Y, Matsuo K, et al. Adipose-derived protein omentin prevents neointimal formation after arterial injury. FASEB J. 2015;29:141–51.PubMedCrossRef
35.
Watanabe K, Watanabe R, Konii H, Shirai R, Sato K, Matsuyama TA, Ishibashi-Ueda H, Koba S, Kobayashi Y, Hirano T, et al. Counteractive effects of omentin-1 against atherogenesis. Cardiovasc Res. 2016;110:118–28.PubMedCrossRef
36.
Herder C, Ouwens DM, Carstensen M, Kowall B, Huth C, Meisinger C, Rathmann W, Roden M, Thorand B. Adiponectin may mediate the association between omentin, circulating lipids and insulin sensitivity: results from the KORA F4 study. Eur J Endocrinol. 2015;172:423–32.PubMedCrossRef
37.
Shibata R, Ouchi N, Takahashi R, Terakura Y, Ohashi K, Ikeda N, Higuchi A, Terasaki H, Kihara S, Murohara T. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr. 2012;4:37.PubMedPubMedCentralCrossRef
38.
Tekce H, Tekce BK, Aktas G, Alcelik A, Sengul E. Serum omentin-1 levels in diabetic and nondiabetic patients with chronic kidney disease. Exp Clin Endocrinol Diabetes. 2014;122:451–6.PubMedCrossRef
39.
Zhou JP, Tong XY, Zhu LP, Luo JM, Luo Y, Bai YP, Li CC, Zhang GG. Plasma Omentin-1 Level as a Predictor of Good Coronary Collateral Circulation. J Atheroscler Thromb. 2017;24:940–8.PubMedPubMedCentralCrossRef
40.
Menzel J, di Giuseppe R, Biemann R, Wittenbecher C, Aleksandrova K, Pischon T, Fritsche A, Schulze MB, Boeing H, Isermann B, et al. Omentin-1 and risk of myocardial infarction and stroke: results from the EPIC-Potsdam cohort study. Atherosclerosis. 2016;251:415–21.PubMedCrossRef
41.
Saely CH, Leiherer A, Muendlein A, Vonbank A, Rein P, Geiger K, Malin C, Drexel H. High plasma omentin predicts cardiovascular events independently from the presence and extent of angiographically determined atherosclerosis. Atherosclerosis. 2016;244:38–43.PubMedCrossRef
42.
Saddic LA, Nicoloro SM, Gupta OT, Czech MP, Gorham J, Shernan SK, Seidman CE, Seidman JG, Aranki SF, Body SC, et al. Joint analysis of left ventricular expression and circulating plasma levels of Omentin after myocardial ischemia. Cardiovasc Diabetol. 2017;16:87.PubMedPubMedCentralCrossRef
43.
Balestrieri ML, Rizzo MR, Barbieri M, Paolisso P, D’Onofrio N, Giovane A, Siniscalchi M, Minicucci F, Sardu C, D’Andrea D, et al. Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment. Diabetes. 2015;64:1395–406.PubMedCrossRef
44.
Sardu C, Barbieri M, Balestrieri ML, Siniscalchi M, Paolisso P, Calabro P, Minicucci F, Signoriello G, Portoghese M, Mone P, et al. Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up. Cardiovasc Diabetol. 2018;17:152.PubMedPubMedCentralCrossRef
45.
Sardu C, D’Onofrio N, Mauro C, Balestrieri ML, Marfella R. Thrombus aspiration in hyperglycemic patients with high inflammation levels in coronary thrombus. J Am Coll Cardiol. 2019;73:530–1.PubMedCrossRef
46.
Gorgui J, Gasbarrino K, Georgakis MK, Karalexi MA, Nauche B, Petridou ET, Daskalopoulou SS. Circulating adiponectin levels in relation to carotid atherosclerotic plaque presence, ischemic stroke risk, and mortality: a systematic review and meta-analyses. Metabolism. 2017;69:51–66.PubMedCrossRef
47.
Gasbarrino K, Zheng H, Hafiane A, Veinot JP, Lai C, Daskalopoulou SS. Decreased adiponectin-mediated signaling through the adipor2 pathway is associated with carotid plaque instability. Stroke. 2017;48:915–24.PubMedCrossRef
48.
Sasso FC, Pafundi PC, Marfella R, Calabro P, Piscione F, Furbatto F, Esposito G, Galiero R, Gragnano F, Rinaldi L, et al. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. Cardiovasc Diabetol. 2019;18:24.PubMedPubMedCentralCrossRef
49.
Marfella R, Rizzo MR, Siniscalchi M, Paolisso P, Barbieri M, Sardu C, Savinelli A, Angelico N, Del Gaudio S, Esposito N, et al. Peri-procedural tight glycemic control during early percutaneous coronary intervention up-regulates endothelial progenitor cell level and differentiation during acute ST-elevation myocardial infarction: effects on myocardial salvage. Int J Cardiol. 2013;168:3954–62.PubMedCrossRef
50.
Marfella R, Sardu C, Balestrieri ML, Siniscalchi M, Minicucci F, Signoriello G, Calabro P, Mauro C, Pieretti G, Coppola A, et al. Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis. Diabetol Metab Syndr. 2018;10:1.PubMedPubMedCentralCrossRef
51.
Marfella R, Sardu C, Calabro P, Siniscalchi M, Minicucci F, Signoriello G, Balestrieri ML, Mauro C, Rizzo MR, Paolisso G, et al. Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: effects of incretin treatment. Diabetes Obes Metab. 2018;20:723–9.PubMedCrossRef
52.
Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care. 2016;39:139–48.PubMedCrossRef
53.
Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, Engstrom G, Evans GW, de Graaf J, Grobbee DE, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA. 2012;308:796–803.CrossRef
54.
Metadata
Title
Plasma omentin levels are inversely associated with atherosclerosis in type 2 diabetes patients with increased plasma adiponectin levels: a cross-sectional study
Authors
Masami Nishimura
Tomoaki Morioka
Mariko Hayashi
Yoshinori Kakutani
Yuko Yamazaki
Masafumi Kurajoh
Katsuhito Mori
Shinya Fukumoto
Atsushi Shioi
Tetsuo Shoji
Masaaki Inaba
Masanori Emoto
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2019
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-019-0973-3

Other articles of this Issue 1/2019

Cardiovascular Diabetology 1/2019 Go to the issue

Original investigation

A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients

Original investigation

Pioglitazone strengthen therapeutic effect of adipose-derived regenerative cells against ischemic cardiomyopathy through enhanced expression of adiponectin and modulation of macrophage phenotype

Original investigation

Cardiac ischemia–reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity

Original investigation

A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients

Original investigation

Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation

Original investigation

Coronary plaque characteristics and epicardial fat tissue in long term survivors of type 1 diabetes identified by coronary computed tomography angiography

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits